Riluzole likely lacks antidepressant efficacy in ketamine non-responders
- PMID: 25139008
- PMCID: PMC4300112
- DOI: 10.1016/j.jpsychires.2014.07.022
Riluzole likely lacks antidepressant efficacy in ketamine non-responders
Keywords: Glutamate; Ketamine; Major depressive disorder; Riluzole; Treatment-resistant depression.
Conflict of interest statement
Drs. Niciu, Ionescu, Richards, Vande Voort, Ballard, Ms. Brutsche and Mr. Luckenbaugh have no potential financial conflicts of interest to disclose. Dr. Furey is listed as a co-inventor on a patent application for the use of scopolamine in major depression, and Dr. Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Drs. Furey and Zarate have assigned their rights in the patent to the U.S. Government but will share a percentage of any royalties that may be received by the Government.
Figures

References
-
- Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526–33. - PMC - PubMed
-
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical